Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
GET THE APP
Hepatitis C Virus Infection In Egypt | 51471
ISSN: 2161-069X
Journal of Gastrointestinal & Digestive System
Open Access
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Egypt has the highest prevalence of hepatitis C virus infection in the world. The prevalence of HCV viremia was estimated
to be 7.3%, and 90% of them have genotype 4. Until 2007, hepatitis C virus treatment was not offered by the government.
In 2007, an Egyptian National Committee for Control of Viral Hepatitis (NCCVH) has been established. Number of patients
treated with PEG-INF and ribavirin was 350,000. A further step in treating HCV was FDA approval of Sofosbuvir in 2013.
Egyptian government made an agreement with the manufacturer company Gilead to decrease the cost of the course for 3
months from 84000$ to 900$. New treatment protocol started in September 2014. The protocol categorized patients into 2
groups: Group 1 - Patients who were eligible to receive interferon were treated with daily Sofosbuvir (400 mg) and weightbased
ribavirin plus weekly peginterferon for 12 weeks and Group 2 - Patients who were not eligible to receive interferon were
treated by daily sofosbuvir (400 mg) plus weight-based ribavirin for 24 weeks. A further step in treating HCV was achieved
after availability of the new drugs, daclatasvir and ritonavir boosted paritaprevir/ombitasvir in Egypt. Treatment protocol
was updated in November 2015. Patients were categorized into 4 groups: 1 - Easy to treat group, was treated by the following
regimen for 12 weeks; sofosbuvir (400 mg) plus daclatasvir (60 mg). 2 - Difficult to treat group, was treated by the following
regimen for 12 weeks; sofosbuvir (400 mg) plus daclatasvir (60 mg) plus ribavirin (600 mg up to 1000 mg). 3 - Third regimen
was for patients with post organ transplantation and patients who failed previous sofosbuvir containing regimen. These patients
were treated by the following regimen for 24 weeks; sofosbuvir (400 mg) plus daclatasvir (60 mg) plus ribavirin (600 mg up to
1000 mg). 4 - Fourth regimen for patients with glomerular filtration rate less than 30 ml/min were treated by ritonavir boosted
paritaprevir/ombitasvir plus ribavirin for 12 weeks. Results of treatment will be mentioned in the presentation.
Biography
Hasan Ahmed El-Garem has completed his MD from Faculty of Medicine, Cairo University and Post-doctoral studies from Amsterdam Medical Centre. He is a Professor of Gastroenterology & Hepatology at Faculty of Medicine, Cairo University. He has published more than 25 papers in reputed journals.